Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Scholar Rock Holding Corp (SRRK) Insider Trading Activity
Healthcare • Biotechnology • 150 employees
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Total Value
-$123,157,769.33
Total Shares
-3,188,533
Average Trade Value
-$3,622,287.33
Most Active Insider
Invus Public Equities, L.P.
Total Activity: $82,397,639
Largest Single Transaction
$66,640,000
by Invus Public Equities, L.P. on Dec 10, 2024
30-Day Activity
1 Transaction
Volume: 1,600,000 shares
Value: $66,640,000
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Dec 10, 2024 | 1,600,000 | $66,640,000 | 9,250,005 (-17.3%) | Sale | ||
|
Chief Medical Officer
Officer
|
Nov 25, 2024 | 200 | $8,144 | 72,855 (-0.3%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 25, 2024 | 3,075 | $122,780 | 73,055 (-4.2%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 25, 2024 | 2,100 | $82,434 | 76,130 (-2.8%) | Sale | |
| Nov 25, 2024 | 149 | $6,106 | 10,850,005 (-0.0%) | Sale | ||
| Nov 25, 2024 | 30,683 | $1,231,585 | 10,850,154 (-0.3%) | Sale | ||
| Nov 25, 2024 | 208,272 | $7,837,504 | 11,051,166 (-1.9%) | Sale | ||
| Nov 25, 2024 | 43,887 | $1,686,670 | 11,007,279 (-0.4%) | Sale | ||
| Nov 25, 2024 | 126,442 | $4,995,774 | 10,880,837 (-1.2%) | Sale | ||
|
Chief Medical Officer
Officer
|
Nov 25, 2024 | 6,375 | $54,761 | 79,230 (+8.0%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 25, 2024 | 1,000 | $38,041 | 78,230 (-1.3%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 22, 2024 | 2,145 | $18,426 | 75,000 (+2.9%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 22, 2024 | 2,145 | $64,372 | 72,855 (-2.9%) | Sale | |
|
Chief Medical Officer
|
Nov 11, 2024 | 2,105 | $63,158 | 72,855 (-2.9%) | Sale | |
|
Chief Medical Officer
|
Nov 11, 2024 | 2,105 | $18,082 | 74,960 (+2.8%) | Exercise/Conversion | |
|
COO CFO
Officer
|
Oct 8, 2024 | 37,187 | $371,870 | 198,275 (+18.8%) | Exercise/Conversion | |
|
COO CFO
Officer
|
Oct 8, 2024 | 37,187 | $1,297,659 | 161,088 (-23.1%) | Sale | |
|
COO CFO
Officer
|
Oct 7, 2024 | 111,972 | $2,867,603 | 255,356 (-43.8%) | Sale | |
|
Chief Medical Officer
Officer
|
Oct 7, 2024 | 39,375 | $1,183,652 | 72,855 (-54.0%) | Sale | |
| Oct 7, 2024 | 510,000 | $15,300,000 | 5,768,609 (-8.8%) | Sale | ||
|
Chief Commercial Officer
Officer
|
Oct 7, 2024 | 28,036 | $717,161 | 51,249 (-54.7%) | Sale | |
|
COO CFO
Officer
|
Oct 7, 2024 | 37,206 | $998,237 | 218,150 (-17.1%) | Sale | |
| Oct 7, 2024 | 510,000 | $14,025,000 | 6,278,609 (-8.1%) | Sale | ||
|
Chief Commercial Officer
Officer
|
Oct 7, 2024 | 30,000 | $300,000 | 79,285 (+37.8%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Oct 7, 2024 | 1,964 | $51,516 | 49,285 (-4.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Oct 7, 2024 | 67,448 | $1,725,893 | 114,782 (-58.8%) | Sale | |
|
Chief Medical Officer
Officer
|
Oct 7, 2024 | 109,375 | $939,531 | 182,230 (+60.0%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Oct 7, 2024 | 2,552 | $66,923 | 112,230 (-2.3%) | Sale | |
|
COO CFO
Officer
|
Oct 7, 2024 | 25,812 | $703,893 | 192,338 (-13.4%) | Sale | |
|
COO CFO
Officer
|
Oct 7, 2024 | 206,240 | $2,852,299 | 367,328 (+56.1%) | Exercise/Conversion | |
| Oct 7, 2024 | 155,713 | $5,060,673 | 5,612,896 (-2.8%) | Sale | ||
|
COO CFO
Officer
|
Oct 7, 2024 | 31,250 | $907,813 | 161,088 (-19.4%) | Sale | |
|
Chief Scientific Officer
|
Sep 16, 2024 | 1,936 | $16,611 | 142,768 (-1.4%) | Sale | |
|
Chro
Officer
|
Aug 16, 2024 | 1,451 | $13,538 | 151,988 (-1.0%) | Sale |